Skip to main content
. Author manuscript; available in PMC: 2008 Jun 16.
Published in final edited form as: J Biol Chem. 2007 Apr 5;282(21):15404–15415. doi: 10.1074/jbc.M701638200

Fig. 5. A CD36-binding peptide prevents myristate-driven cGMP accumulation in endothelial cells.

Fig. 5

HUVEC cells plated at 5 × 103 cells/well were weaned over 48 h from serum then treated in EBM containing 0.1% FAF-BSA and pre-treated with the translocase inhibiting CD36-binding peptide (p907, A) or control (p906, B) (10 µM) for 15 min, treated with myristate (10 µM) for 5 min, and cGMP levels determined via ELISA.